Paliperidon Ratiopharm (Paliperidone Palmitate)

Paliperidon Ratiopharm is an antipsychotic medication used in the management of schizophrenia and related psychotic disorders.

• Schizophrenia: Reduces the frequency and severity of psychotic episodes, helping maintain stability.
• Schizoaffective disorder: Alleviates mood‑related symptoms while controlling psychosis.
• Maintenance therapy after acute stabilization: Provides sustained symptom control with once‑monthly injections.

• Paliperidone palmitate is a long‑acting pro‑drug of paliperidone that slowly releases the active molecule after intramuscular injection. The active compound antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in brain pathways implicated in psychosis and helping to restore a more balanced dopaminergic and serotonergic tone.

Paliperidon Ratiopharm may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Injection site pain or erythema.
• Weight gain.
• Fatigue or somnolence.
• Constipation.
• Increased prolactin levels.

Serious or Rare Side Effects

• Extrapyramidal symptoms such as dystonia or akathisia.
• Neuroleptic malignant syndrome.
• Severe orthostatic hypotension.
• Tardive dyskinesia.
• Hyperglycaemia or new‑onset diabetes.
• Seizures.

When prescribing Paliperidon Ratiopharm, clinicians should consider several safety aspects.

• Cardiovascular assessment: Evaluate for history of arrhythmias or QT prolongation before initiating therapy.
• Metabolic monitoring: Regularly check weight, glucose and lipid profiles during treatment.
• Prolactin monitoring: Observe for signs of hyperprolactinaemia such as galactorrhoea.
• Pregnancy and lactation: Use only if the potential benefit outweighs risk; discuss with the patient.
• Elderly patients: Start at lower doses and monitor for sedation and orthostatic falls.
• Store at ambient temperature: keep in the original packaging .

Paliperidon Ratiopharm interacts with several medications that can alter its safety or efficacy.

Major Interactions (Avoid)

• CYP C‑ C  C ");

Moderate Interactions (Met­ "); t  "); """